Dynal has announced today the release of a new research tool in its immunotherapy range that allow researchers to isolate and collect T cells from immunocompromised patients for ex vivo stimulation and expansion in a sterile environment.
The function has played a major part in certain clinical applications, which include autoimmune diseases as well as gene and stem cell applications. Boosted T cells, if reinfused, have the potential to strengthen the individual's immune system to fight diseases, for example cancer and HIV.
The Dynabeads ClinExVivo CD3/CD28 superparamagnetic beads are designed with an optimised surface covered with primary CD3 and co-stimulatory CD28 antibodies.
Following a short ex vivo incubation with the patient's sample, the beads bind with the T cells. The beads and bound T cells are separated from the rest of the sample using the special Dynal ClinExVivo
MPC magnet. Researchers then stimulate and expand the T cells ex vivo with Dynabeads ClinExVivo CD3/CD28 in a sterile environment prior to reintroduction to the patient.
"Already this innovative technology has been used for several phase I/II trials in cancer patients," said Dynal's international product manager, Erik Ruud.
"Data from studies using ex vivo manipulated T cells in cancer and vaccine therapy were recently presented at the International Society for Cell Therapy (ISCT) conference during a special symposium on "T Cell-based Immunotherapeutic Strategies."
Dynabeads are superparamagnetic, which exhibit magnetic properties only when placed within a magnetic field and show no residual magnetism when removed from this field.
In the US, Dynabeads ClinExVivo CD3/CD28 are available for clinical applications only under an approved IND application.